Tucked hauv nws Q4 cov nyiaj tau los tshaj tawm xov xwm, BioCryst Pharmaceuticals Inc (Nasdaq: BCRX) tau tshaj tawm qhov kev poob qis ntawm qhov kev kawm thaum ntxov BCX10013.
Lub tuam txhab tau sau tseg tsis ntev los no cov kev soj ntsuam txog koob tshuaj nyob rau hauv ib qho kev kawm tsis tu ncua BCX10013 tsis tu ncua yuav ncua kev kho mob.
BioCryst tau npaj ua ntej BCX10013 rau hauv cov neeg mob kev tshawb fawb nyob rau hauv nruab nrab-2023, nrog rau cov neeg mob uas muaj paroxysmal nocturnal hemoglobinuria (PNH), los soj ntsuam ib zaug ib hnub twg.
Thaum Lub Ib Hlis, lub tuam txhab tshaj tawm cov ntaub ntawv thawj zaug los ntawm kev txuas ntxiv mus rau theem 1 ib zaug nce koob tshuaj (SAD) thiab ntau qhov kev nce qib (MAD) kev sim hauv cov neeg ua haujlwm noj qab haus huv.
Nws tau pom sai, txhawb nqa, thiab> 97 feem pua ntawm kev tawm tsam ntawm cov txheej txheem ntxiv txoj hauv kev (AP) 24 teev tom qab ib koob 110 mg thiab tias BCX10013 tau muaj kev nyab xeeb thiab feem ntau ua tau zoo ntawm txhua qhov koob tshuaj tau kawm txog hnub no.
Needham sau tias lawv ntseeg tias qhov muag-tawm yog dhau lawm thiab tias BCRX qhov 25% YTD poob qis coj nws cov shares mus rau theem uas tsis ua tiav qhov kev muag khoom ntawm Orladeyo (2023 kev taw qhia muag ntawm ≥ $ 320 lab, + 27% Y / Y) thiab kev loj hlob trajectory.
Tus kws tshuaj ntsuam tau hloov kho cov Tshuag mus Yuav los ntawm Tuav nrog tus nqi phiaj ntawm $ 14.
Tus kws tshuaj ntsuam xav tias Orladeyo tuaj yeem ua tiav kev muag khoom ntawm $ 700 lab, muab qhov kev sib tw los ntawm lwm qhov ncauj HAE prophylactic tsis zoo li tsawg kawg 5-7 xyoo.
BCRX's OpEx kev siv nyiaj yog siab, tab sis lub tuam txhab tau txais txiaj ntsig zoo, nrog cov nyiaj tshuav ntawm $ 443.9 lab. BCX10013 kev poob qis tuaj yeem ua rau R & D kev siv nyiaj txiav uas ua rau kom muaj kev vam meej kom tawg, muaj peev xwm ntxov li 2024.
Nqe Nqis: BCRX shares tau nce 12.33% ntawm $ 9.70 ntawm daim tshev kawg hnub Wednesday.
Qhov ntsuas tseeb rau BCRX
Hnub | Tshaj tawm | Action | Los ntawm | Yuav |
|---|---|---|---|---|
Dec 2021 | Xaiv Tsa | Pib Kev Npam Ntawm | Txoj Kev Ua Txhaum | |
Nov 2021 | RBC Peev | Txij nkawm | Sector Ua | |
Nov 2021 | Barclays | Txij nkawm | Rog |
Saib Ntau Cov Kev Ntsuas Ntsuas rau BCRX
Saib Qhov Ntsuam Kev Ntsuam Xyuas Cov Ntaus Tawm Tshiab
Tsis txhob nco lub sijhawm ceeb toom ntawm koj cov khoom lag luam - koom Lub Npe Lub Npe Pro dawb! Sim cov cuab yeej uas yuav pab koj nqis peev smarter, sai dua, thiab zoo dua.
Tshooj no Tus kws tshuaj ntsuam pom qhov ntxim nyiam nkag tau tom qab BioCryst's Pipeline Setback Ameslikas nyob rau hauv benzinga.com
.
© 2023 Benzinga.com. Benzinga tsis muab lus qhia txog peev. Qoob loo.
Tau qhov twg los: https://finance.yahoo.com/news/analyst-sees-attractive-entry-opportunity-193122895.html